= 12); stage IIA ( n = 5); stage IIB ( n = 1); stage IIIB ( n = 3); stage IV ( n = 3)). Of these, 3 insulinoma (stage IIA ( n = 2); stage IIIB ( n = 1)) occurred in the context of MEN-1. We also identified one case of a pro-insulin/GLP-1-secreting
Search Results
Benjamin G Challis, Andrew S Powlson, Ruth T Casey, Carla Pearson, Brian Y Lam, Marcella Ma, Deborah Pitfield, Giles S H Yeo, Edmund Godfrey, Heok K Cheow, V Krishna Chatterjee, Nicholas R Carroll, Ashley Shaw, John R Buscombe, and Helen L Simpson
Benjamin Paul Green, Javier Thomas Gonzalez, Kevin Thomas, Emma Stevenson, and Penny Louise Sheena Rumbold
tract, pancreas, and adipose, act to influence the physiological mechanisms controlling energy regulation, eliciting divergent actions on feeding behaviour and metabolism (1) . In humans, hormonal peptides such as glucagon-like peptide-1 (GLP1) (2
Kim K B Clemmensen, Jonas S Quist, Dorte Vistisen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Jens J Holst, Torsten Lauritzen, Marit E Jørgensen, Signe Torekov, and Kristine Færch
should be 3.0, not 3.9, the value for Adjusted Estimate of Fasting plasma glucagon should be 0.0 not 0.3, and the value for Unadjusted Estimate of 30 min plasma GLP-1 should be −0.5 not −1.5. These errors do not affect the results or conclusions. The
Annieke C G van Baar, Andrei Prodan, Camilla D Wahlgren, Steen S Poulsen, Filip K Knop, Albert K Groen, Jacques J Bergman, Max Nieuwdorp, and Evgeni Levin
, metabolic syndrome (MetS) and type 2 diabetes ( 1 ). The gut incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), produced by enteroendocrine L cells and K cells, respectively, are intimately involved in
Riying Liang, Meijun Wang, Chang Fu, Hua Liang, Hongrong Deng, Ying Tan, Fen Xu, and Mengyin Cai
fibrosis and glomerulosclerosis ( 6 , 7 ). Despite the public health correlation between obesity and kidney injury, there is no effective drug therapy approved for kidney damage. Glucagon-like peptide-1 (GLP-1) is mainly secreted from intestinal L cells
David S Mathiesen, Jonatan I Bagger, Katrine B Hansen, Anders E Junker, Astrid Plamboeck, Signe Harring, Thomas Idorn, Mads Hornum, Jens J Holst, Anna E Jonsson, Torben Hansen, Tina Vilsbøll, Asger Lund, and Filip K Knop
effect is mediated by the two gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) ( 6 ). These hormones are secreted from enteroendocrine K and L cells, situated in the intestinal mucosa, in response to
Marloes Emous, Merel van den Broek, Ragnhild B Wijma, Loek J M de Heide, Gertjan van Dijk, Anke Laskewitz, Erik Totté, Bruce H R Wolffenbuttel, and André P van Beek
). Glucagon-like peptide-1 (GLP-1) is assumed to play a pivotal role in the pathophysiology of PHH, most convincingly because the GLP-1 antagonist exendin (9-39) prevents postprandial hyperinsulinaemia and the subsequent hypoglycaemia in people with severe
Metin Guclu, Sinem Kiyici, Zulfiye Gul, and Sinan Cavun
, including insulin, sulfonylureas and thiazolidinediones, cause weight gain instead of weight loss during the management period ( 3 ). Glucagon-like peptide-1 (GLP-1) receptor agonists are used in the treatment of patients with type 2 diabetes mellitus, and
Malin Nylander, Signe Frøssing, Caroline Kistorp, Jens Faber, and Sven O Skouby
mild degree ( 24 ) and might to some extent diminish the increased thrombin generation induced by oral contraceptives, as recently investigated ( 12 ). Glucagonlike peptide-1 (GLP-1) analogs are commonly used in type 2 diabetes and obesity, where they
Alexis Sudlow, Carel W le Roux, and Dimitri J Pournaras
loss produced by the initial operation involving the removal of a segment of the stomach prompted surgeons to undertake it as a procedure in its own right. The metabolic effects of SG are thought to be the result of a combination of increased GLP-1 and
